

Crbn-I391V

| | |
|--------|--|
| 系統名 | C57BL/6Smoc- <i>Crbn</i> ^{em1(I391V)Smoc} |
| SMOC番号 | NM-KI-200331 |
| 維持形態 | Embryo cryopreservation |

遺伝子の概要

| | | |
|---------------------|-----------------------|--|
| Gene Symbol Crbn | Synonyms | piL; AF229032; AW108261; 2610203G15Rik; 2900045007Rik |
| | NCBI ID | 58799 |
| | MGI ID | 1913277 |
| | Ensembl ID | ENSMUSG00000005362 |
| | Human Ortholog | CRBN |

説明

These mice carry a p.I391V mutation of *Crbn* gene.

*Literature published using this strain should indicate: *Crbn*-I391V mice (Cat. NO. NM-KI-200331) were purchased from Shanghai Model Organisms Center, Inc..

表現型データ




Fig1. CRBN modulators induced IL-2 secretion and Aiolos degradation in *Crbn*-I391V point mutation mice.

(A) Analysis of IL-2 production in naive CD4⁺ T cells by ELISA. After Lenalidomide 5000nM or Pomalidomide 5000nM treatment, CRBN modulators induced IL-2 secretion in naive CD4⁺ T cells.

(B) Analysis of Aiolos expression in the spleen by FACS. After Lenalidomide 10uM or Pomalidomide 5000nM treatment, the AIOLOS expression decreased obviously in CD19+ B cells and CD3+ T cells. The results have shown that this Crbn-I391V KI mice model can be used to study the in vivo toxicity and efficacy of CRBN target drugs. (In collaboration with partners)
